Report Scope & Overview:
Non-Alcoholic Steatohepatitis Treatment Market valued at US$ 14,624.2 Mn in 2022 and is forecast to reach a value of US$ 63,354.6 Mn by 2030 at a CAGR of 20.13% between 2023 and 2030.
Non-Alcoholic Steatohepatitis Treatment Market Overview:
Global Non-Alcoholic Steatohepatitis Treatment Market research provides insights into consumer behavior, industry trends, and market competition through the use of various research techniques, including surveys, interviews, and data analysis. The industry serves a wide range of clients, including businesses, government agencies, and non-profit organizations. Non-Alcoholic Steatohepatitis Treatment Market is highly diverse, with a range of services and specialties, including quantitative and qualitative research, brand research, product testing, customer satisfaction research, and competitive analysis.
Overall, Non-Alcoholic Steatohepatitis Treatment market plays a crucial role in helping businesses and organizations make informed decisions based on data-driven insights. As the demand for data-driven decision-making continues to grow, Non-Alcoholic Steatohepatitis Treatment market research is expected to experience further growth and innovation in the coming years.
Global Non-Alcoholic Steatohepatitis Treatment Market research provides insights into consumer behavior, industry trends, and market competition through the use of various research techniques, including surveys, interviews, and data analysis. The industry serves a wide range of clients, including businesses, government agencies, and non-profit organizations. Non-Alcoholic Steatohepatitis Treatment Market is highly diverse, with a range of services and specialties, including quantitative and qualitative research, brand research, product testing, customer satisfaction research, and competitive analysis.
Overall, Non-Alcoholic Steatohepatitis Treatment market plays a crucial role in helping businesses and organizations make informed decisions based on data-driven insights. As the demand for data-driven decision-making continues to grow, Non-Alcoholic Steatohepatitis Treatment market research is expected to experience further growth and innovation in the coming years.
DESCIMG1
Non-Alcoholic Steatohepatitis Treatment Market Key Drivers
Increasing Prevalence of NASH: The rising prevalence of obesity, type 2 diabetes, and metabolic syndrome is driving an increase in the incidence of NASH. This has created a substantial patient population in need of treatment.
Awareness and Diagnosis: Improved awareness of NASH among healthcare providers and patients, along with advances in diagnostic tools such as non-invasive liver fibrosis assessment, has led to more accurate and timely diagnoses.
Liver Disease Progression: NASH can progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), emphasizing the need for effective treatments to prevent disease progression and complications.
Emerging Biomarkers: The identification of new biomarkers and non-invasive diagnostic tests for NASH and liver fibrosis is aiding in early detection and patient stratification.
Regulatory Focus: Regulatory agencies, such as the FDA and EMA, have recognized NASH as a serious health concern and are working to establish clear pathways for drug development and approval.
Unmet Medical Need: Currently, there are no approved pharmacological treatments specifically for NASH, creating a substantial unmet medical need that pharmaceutical companies are eager to address.
Market Segmentations:Global Non-Alcoholic Steatohepatitis Treatment Market: By Company
• Intercept Pharmaceuticals
• Galmed Pharmaceuticals
• Inventiva Pharma
• AbbVie Inc.
• Galectin Therapeutics Inc.
• Madrigal Pharmaceuticals
• NGM Biopharmaceuticals Inc.
• Novo Nordisk A/S
• Bristol Myers Squibb
• Gilead Sciences Inc.
Global Non-Alcoholic Steatohepatitis Treatment Market: By Type
• Vitamin E and Pioglitazone
• Obeticholic Acid (OCA)
• Lanifibranor
• Semaglutide
• Resmetirom
• Aramchol
• Cenicriviroc
• Others
Global Non-Alcoholic Steatohepatitis Treatment Market: By Application
• Hospital Pharmacies
• Retail & Specialty Pharmacies
• Others
Global Non-Alcoholic Steatohepatitis Treatment Market: Regional Analysis
All the regional segmentation has been studied based on recent and future trends, and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Non-Alcoholic Steatohepatitis Treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.
| Report Attribute/Metric | Details |
| Market Size 2022 | US$ 14,624.2 Mn |
| Market Size 2030 | US$ 63,354.6 Mn |
| Compound Annual Growth Rate (CAGR) | 20.13%(2023-2030) |
| Base Year | 2022 |
| Forecast Period | 2023-2032 |
| Historical Data | 2018-2022 |
| Forecast Units | Value (US$ Mn) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| By Type | • Vitamin E and Pioglitazone • Obeticholic Acid (OCA) • Lanifibranor • Semaglutide • Resmetirom • Aramchol • Cenicriviroc • Others |
| By Application | • Hospital Pharmacies • Retail & Specialty Pharmacies |
| Key Companies Profiled | • Intercept Pharmaceuticals • Galmed Pharmaceuticals • Inventiva Pharma • AbbVie Inc. • Galectin Therapeutics Inc. • Madrigal Pharmaceuticals • NGM Biopharmaceuticals Inc. • Novo Nordisk A/S • Bristol Myers Squibb • Gilead Sciences Inc. |
| Regions and Key Countries Covered | U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America |
| Customization Scope | Available on Request |
Reasons to Purchase Non-Alcoholic Steatohepatitis Treatment Market Report:
• To gain insights into market trends and dynamics: this reports provide valuable insights into industry trends and dynamics, including market size, growth rates, and key drivers and challenges.
• To identify key players and competitors: this research reports can help businesses identify key players and competitors in their industry, including their market share, strategies, and strengths and weaknesses.
• To understand consumer behavior: this research reports can provide valuable insights into consumer behavior, including their preferences, purchasing habits, and demographics.
• To evaluate market opportunities: this research reports can help businesses evaluate market opportunities, including potential new products or services, new markets, and emerging trends.
• To make informed business decisions: this research reports provide businesses with data-driven insights that can help them make informed business decisions, including strategic planning, product development, and marketing and advertising strategies.
Overall, market research reports provide businesses and organizations with valuable information that can help them make informed decisions and stay competitive in their industry. They can provide a solid foundation for business planning, strategy development, and decision-making.
Objectives of Non-Alcoholic Steatohepatitis Treatment Market Study:
The objectives of Non-Alcoholic Steatohepatitis Treatment market research report may vary depending on the specific needs and goals of the business or organization commissioning the report. However, some common objectives of market research reports include:
• Understanding the market size and potential: One of the primary objectives of Non-Alcoholic Steatohepatitis Treatment market research is to understand the size and potential of a particular market. This includes analyzing market trends and dynamics, identifying key players and competitors, and assessing the demand for products or services.
• Identifying target customers and segments: this market research reports can help businesses identify and understand their target customers and market segments, including their preferences, behaviors, and demographics. This information can be used to develop targeted marketing and advertising strategies.
• Evaluating product or service performance: this market research reports can provide valuable insights into the performance of products or services, including customer satisfaction, product usage, and product quality. This information can be used to improve products or services and enhance customer satisfaction.
• Assessing market opportunities and threats: this market research reports can help businesses identify potential market opportunities and threats, including emerging trends, competitive threats, and new market entrants. This information can be used to develop strategic plans and make informed business decisions.
• Developing effective marketing and advertising strategies: this market research reports can help businesses develop effective marketing and advertising strategies by providing insights into customer preferences and behavior, competitive dynamics, and market trends. This can help businesses improve brand awareness, customer engagement, and overall marketing effectiveness.
Overall, the objectives of Non-Alcoholic Steatohepatitis Treatment market research report are to provide businesses and organizations with valuable insights and data-driven recommendations that can help them make informed business decisions and stay competitive in their industry.
Frequently Asked Questions
Non-Alcoholic Steatohepatitis Treatment Market valued at US$ 14,624.2 Mn in 2022 and is forecast to reach a value of US$ 63,354.6 Mn by 2030 at a CAGR of 20.13% between 2023 and 2030.
Information on risk factors, including obesity, insulin resistance, and genetic predisposition, and their contributions to NASH development may be discussed.
The report might outline existing treatment options, such as dietary changes, exercise, and potential pharmacological interventions, and reference relevant clinical guidelines.
Information on the unmet medical need for NASH treatment, including the absence of approved drugs, and its consequences for patients and healthcare systems may be highlighted.
The report could provide an overview of the NASH drug pipeline, potential mechanisms of action, and clinical trial progress.
TABLE OF CONTENT
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis Treatment Market Size Growth Rate by Type: 2018 VS 2023 VS 2032
1.2.2 Vitamin E and Pioglitazone
1.2.3 Obeticholic Acid (OCA)
1.2.4 Lanifibranor
1.2.5 Semaglutide
1.2.6 Resmetirom
1.2.7 Aramchol
1.2.8 Cenicriviroc
1.2.9 Others
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis Treatment Market Growth by Application: 2018 VS 2023 VS 2032
1.3.2 Hospital Pharmacies
1.3.3 Retail & Specialty Pharmacies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis Treatment Market Perspective (2017-2032)
2.2 Non-Alcoholic Steatohepatitis Treatment Growth Trends by Region
2.2.1 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Region: 2018 VS 2023 VS 2032
2.2.2 Non-Alcoholic Steatohepatitis Treatment Historic Market Size by Region (2017-2023)
2.2.3 Non-Alcoholic Steatohepatitis Treatment Forecasted Market Size by Region (2023-2032)
2.3 Non-Alcoholic Steatohepatitis Treatment Market Dynamics
2.3.1 Non-Alcoholic Steatohepatitis Treatment Industry Trends
2.3.2 Non-Alcoholic Steatohepatitis Treatment Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis Treatment Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis Treatment Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis Treatment Players by Revenue (2017-2023)
3.1.2 Global Non-Alcoholic Steatohepatitis Treatment Revenue Market Share by Players (2017-2023)
3.2 Global Non-Alcoholic Steatohepatitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis Treatment Revenue
3.4 Global Non-Alcoholic Steatohepatitis Treatment Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis Treatment Revenue in 2022
3.5 Non-Alcoholic Steatohepatitis Treatment Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis Treatment Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis Treatment Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis Treatment Historic Market Size by Type (2017-2023)
4.2 Global Non-Alcoholic Steatohepatitis Treatment Forecasted Market Size by Type (2023-2032)
5 Non-Alcoholic Steatohepatitis Treatment Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis Treatment Historic Market Size by Application (2017-2023)
5.2 Global Non-Alcoholic Steatohepatitis Treatment Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
6.2 North America Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2018 VS 2023 VS 2032
6.3 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2017-2023)
6.4 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2023-2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
7.2 Europe Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2018 VS 2023 VS 2032
7.3 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2017-2023)
7.4 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2023-2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Region: 2018 VS 2023 VS 2032
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Region (2017-2023)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Region (2023-2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
9.2 Latin America Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2018 VS 2023 VS 2032
9.3 Latin America Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2017-2023)
9.4 Latin America Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2023-2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2018 VS 2023 VS 2032
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2017-2023)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2023-2032)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Intercept Pharmaceuticals
11.1.1 Intercept Pharmaceuticals Company Detail
11.1.2 Intercept Pharmaceuticals Business Overview
11.1.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Introduction
11.1.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.1.5 Intercept Pharmaceuticals Recent Development
11.2 Galmed Pharmaceuticals
11.2.1 Galmed Pharmaceuticals Company Detail
11.2.2 Galmed Pharmaceuticals Business Overview
11.2.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Introduction
11.2.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.2.5 Galmed Pharmaceuticals Recent Development
11.3 Inventiva Pharma
11.3.1 Inventiva Pharma Company Detail
11.3.2 Inventiva Pharma Business Overview
11.3.3 Inventiva Pharma Non-Alcoholic Steatohepatitis Treatment Introduction
11.3.4 Inventiva Pharma Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.3.5 Inventiva Pharma Recent Development
11.4 AbbVie Inc.
11.4.1 AbbVie Inc. Company Detail
11.4.2 AbbVie Inc. Business Overview
11.4.3 AbbVie Inc. Non-Alcoholic Steatohepatitis Treatment Introduction
11.4.4 AbbVie Inc. Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.4.5 AbbVie Inc. Recent Development
11.5 Galectin Therapeutics Inc.
11.5.1 Galectin Therapeutics Inc. Company Detail
11.5.2 Galectin Therapeutics Inc. Business Overview
11.5.3 Galectin Therapeutics Inc. Non-Alcoholic Steatohepatitis Treatment Introduction
11.5.4 Galectin Therapeutics Inc. Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.5.5 Galectin Therapeutics Inc. Recent Development
11.6 Madrigal Pharmaceuticals
11.6.1 Madrigal Pharmaceuticals Company Detail
11.6.2 Madrigal Pharmaceuticals Business Overview
11.6.3 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Introduction
11.6.4 Madrigal Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.6.5 Madrigal Pharmaceuticals Recent Development
11.7 NGM Biopharmaceuticals Inc.
11.7.1 NGM Biopharmaceuticals Inc. Company Detail
11.7.2 NGM Biopharmaceuticals Inc. Business Overview
11.7.3 NGM Biopharmaceuticals Inc. Non-Alcoholic Steatohepatitis Treatment Introduction
11.7.4 NGM Biopharmaceuticals Inc. Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.7.5 NGM Biopharmaceuticals Inc. Recent Development
11.8 Novo Nordisk A/S
11.8.1 Novo Nordisk A/S Company Detail
11.8.2 Novo Nordisk A/S Business Overview
11.8.3 Novo Nordisk A/S Non-Alcoholic Steatohepatitis Treatment Introduction
11.8.4 Novo Nordisk A/S Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.8.5 Novo Nordisk A/S Recent Development
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Detail
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Treatment Introduction
11.9.4 Bristol Myers Squibb Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.9.5 Bristol Myers Squibb Recent Development
11.10 Gilead Sciences Inc.
11.10.1 Gilead Sciences Inc. Company Detail
11.10.2 Gilead Sciences Inc. Business Overview
11.10.3 Gilead Sciences Inc. Non-Alcoholic Steatohepatitis Treatment Introduction
11.10.4 Gilead Sciences Inc. Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.10.5 Gilead Sciences Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis Treatment Market Size Growth Rate by Type: 2018 VS 2023 VS 2032
1.2.2 Vitamin E and Pioglitazone
1.2.3 Obeticholic Acid (OCA)
1.2.4 Lanifibranor
1.2.5 Semaglutide
1.2.6 Resmetirom
1.2.7 Aramchol
1.2.8 Cenicriviroc
1.2.9 Others
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis Treatment Market Growth by Application: 2018 VS 2023 VS 2032
1.3.2 Hospital Pharmacies
1.3.3 Retail & Specialty Pharmacies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis Treatment Market Perspective (2017-2032)
2.2 Non-Alcoholic Steatohepatitis Treatment Growth Trends by Region
2.2.1 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Region: 2018 VS 2023 VS 2032
2.2.2 Non-Alcoholic Steatohepatitis Treatment Historic Market Size by Region (2017-2023)
2.2.3 Non-Alcoholic Steatohepatitis Treatment Forecasted Market Size by Region (2023-2032)
2.3 Non-Alcoholic Steatohepatitis Treatment Market Dynamics
2.3.1 Non-Alcoholic Steatohepatitis Treatment Industry Trends
2.3.2 Non-Alcoholic Steatohepatitis Treatment Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis Treatment Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis Treatment Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis Treatment Players by Revenue (2017-2023)
3.1.2 Global Non-Alcoholic Steatohepatitis Treatment Revenue Market Share by Players (2017-2023)
3.2 Global Non-Alcoholic Steatohepatitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis Treatment Revenue
3.4 Global Non-Alcoholic Steatohepatitis Treatment Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis Treatment Revenue in 2022
3.5 Non-Alcoholic Steatohepatitis Treatment Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis Treatment Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis Treatment Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis Treatment Historic Market Size by Type (2017-2023)
4.2 Global Non-Alcoholic Steatohepatitis Treatment Forecasted Market Size by Type (2023-2032)
5 Non-Alcoholic Steatohepatitis Treatment Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis Treatment Historic Market Size by Application (2017-2023)
5.2 Global Non-Alcoholic Steatohepatitis Treatment Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
6.2 North America Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2018 VS 2023 VS 2032
6.3 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2017-2023)
6.4 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2023-2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
7.2 Europe Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2018 VS 2023 VS 2032
7.3 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2017-2023)
7.4 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2023-2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Region: 2018 VS 2023 VS 2032
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Region (2017-2023)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Region (2023-2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
9.2 Latin America Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2018 VS 2023 VS 2032
9.3 Latin America Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2017-2023)
9.4 Latin America Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2023-2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Size (2017-2032)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2018 VS 2023 VS 2032
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2017-2023)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis Treatment Market Size by Country (2023-2032)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Intercept Pharmaceuticals
11.1.1 Intercept Pharmaceuticals Company Detail
11.1.2 Intercept Pharmaceuticals Business Overview
11.1.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Introduction
11.1.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.1.5 Intercept Pharmaceuticals Recent Development
11.2 Galmed Pharmaceuticals
11.2.1 Galmed Pharmaceuticals Company Detail
11.2.2 Galmed Pharmaceuticals Business Overview
11.2.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Introduction
11.2.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.2.5 Galmed Pharmaceuticals Recent Development
11.3 Inventiva Pharma
11.3.1 Inventiva Pharma Company Detail
11.3.2 Inventiva Pharma Business Overview
11.3.3 Inventiva Pharma Non-Alcoholic Steatohepatitis Treatment Introduction
11.3.4 Inventiva Pharma Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.3.5 Inventiva Pharma Recent Development
11.4 AbbVie Inc.
11.4.1 AbbVie Inc. Company Detail
11.4.2 AbbVie Inc. Business Overview
11.4.3 AbbVie Inc. Non-Alcoholic Steatohepatitis Treatment Introduction
11.4.4 AbbVie Inc. Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.4.5 AbbVie Inc. Recent Development
11.5 Galectin Therapeutics Inc.
11.5.1 Galectin Therapeutics Inc. Company Detail
11.5.2 Galectin Therapeutics Inc. Business Overview
11.5.3 Galectin Therapeutics Inc. Non-Alcoholic Steatohepatitis Treatment Introduction
11.5.4 Galectin Therapeutics Inc. Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.5.5 Galectin Therapeutics Inc. Recent Development
11.6 Madrigal Pharmaceuticals
11.6.1 Madrigal Pharmaceuticals Company Detail
11.6.2 Madrigal Pharmaceuticals Business Overview
11.6.3 Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Treatment Introduction
11.6.4 Madrigal Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.6.5 Madrigal Pharmaceuticals Recent Development
11.7 NGM Biopharmaceuticals Inc.
11.7.1 NGM Biopharmaceuticals Inc. Company Detail
11.7.2 NGM Biopharmaceuticals Inc. Business Overview
11.7.3 NGM Biopharmaceuticals Inc. Non-Alcoholic Steatohepatitis Treatment Introduction
11.7.4 NGM Biopharmaceuticals Inc. Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.7.5 NGM Biopharmaceuticals Inc. Recent Development
11.8 Novo Nordisk A/S
11.8.1 Novo Nordisk A/S Company Detail
11.8.2 Novo Nordisk A/S Business Overview
11.8.3 Novo Nordisk A/S Non-Alcoholic Steatohepatitis Treatment Introduction
11.8.4 Novo Nordisk A/S Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.8.5 Novo Nordisk A/S Recent Development
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Detail
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis Treatment Introduction
11.9.4 Bristol Myers Squibb Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.9.5 Bristol Myers Squibb Recent Development
11.10 Gilead Sciences Inc.
11.10.1 Gilead Sciences Inc. Company Detail
11.10.2 Gilead Sciences Inc. Business Overview
11.10.3 Gilead Sciences Inc. Non-Alcoholic Steatohepatitis Treatment Introduction
11.10.4 Gilead Sciences Inc. Revenue in Non-Alcoholic Steatohepatitis Treatment Business (2017-2023)
11.10.5 Gilead Sciences Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Intercept Pharmaceuticals
Galmed Pharmaceuticals
Inventiva Pharma
AbbVie Inc.
Galectin Therapeutics Inc.
Madrigal Pharmaceuticals
NGM Biopharmaceuticals Inc.
Novo Nordisk A/S
Bristol Myers Squibb
Gilead Sciences Inc.
In Vitro Diagnostics Quality Control Market
Global In Vitro Diagnostics Quality Control Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast
Ileostomy Market
Global Ileostomy Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast
Human Papillomavirus Vaccine Market
Global Human Papillomavirus Vaccine Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast
Hospital Acquired Pneumonia Drugs Market
Global Hospital Acquired Pneumonia Drugs Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast